Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

54 Press Releases
DateTitleCompany
27 Nov 12 Sensipar, Fosrenol and Renagel/Renvela are Likely to be Negatively Impacted in 2014 When Oral Medications Become Included in the Dialysis Bundle, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
10 Sep 12 Despite Krystexxa’s Availability in the U.S. for 18 Months, Aided Awareness and Familiarity with Krystexxa is Low Among Physicians in the EU5 Countries, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
21 Aug 12 Melanoma Treatment is Undergoing Dramatic Changes as Yervoy and Zelboraf Rapidly Penetrate the Metastatic Patient Population in the U.S. and Europe; However, Drug Usage and BRAF Screening in Europe is Lower Compared to the U.S. Market BioTrends Research Group LLC,
Published by
Business Wire
07 Jun 12 Despite the Availability of Newer Treatment Options Such as Uloric and Krystexxa, the Majority of Gout Patients on Uric Acid Lowering Therapy Fail to Achieve Control of Serum Urate Levels, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
30 May 12 Six Months Post-Launch, Trial and Usage of Orencia SC is Continuing to Increase, Yet It is Still Viewed as a Second-Line Therapy After Anti-TNF Agents for Rheumatoid Arthritis Based on a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
08 May 12 Concerns over Drug Resistance in Gram-Negative Infections Has Led to the Uptake of Drugs Typically Used for Later Lines of Therapy, Including Meropenem, Merck’s Primaxin and Invanz, Janssen’s Doribax, Pfizer’s Tygacil and Colistin BioTrends Research Group LLC,
Published by
Business Wire
03 May 12 BioTrends Announces a New Syndicated Report Series Entitled LaunchTrends®: Omontys BioTrends Research Group LLC,
Published by
Business Wire
02 May 12 Teflaro Continues to Gain Increased Market Share in the U.S. Hospital Setting among ID Specialists and Internists Twelve Months Post-Launch, According to a Recent AMR/BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
23 Apr 12 U.S. Retinal Specialists Report That Dosing Convenience Continues to Drive Regeneron’s Eylea Share Growth in the Wet AMD Market Three Months after Launch, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
19 Apr 12 In the Treatment of Advanced NSCLC, Two Thirds of Oncologists Agree There is a Higher Unmet Need in Squamous-Cell Patients Compared to Non-Squamous Patients Because of a Reliance on Chemotherapy in the Squamous-Cell Setting BioTrends Research Group LLC,
Published by
Business Wire
18 Apr 12 Despite a Slight Increase in the Use of Biologic Agents to Treat Psoriasis in the Past Year, Dermatologists in the EU Are Not Expected to Drastically Change Their Future Prescribing Habits BioTrends Research Group LLC,
Published by
Business Wire
17 Apr 12 Takeda’s Uloric Continues to Penetrate Moderate to Severe Gout Patients, but Allopurinol Remains Market Share Leader According to Latest BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
16 Apr 12 For the Treatment of Advanced Non-Small-Cell Lung Cancer, Medical Oncologists Report That They are Rapidly Adopting the ALK-Positive Test into Their Treatment Practices to Identify Appropriate Patients for Xalkori (crizotinib) BioTrends Research Group LLC,
Published by
Business Wire
12 Apr 12 Renal Anemia Practice Patterns in the U.S. Chronic Kidney Disease and Dialysis Markets Experienced a Pronounced Shift since the ESA Label Change and the Implementation of the Prospective Payment System BioTrends Research Group LLC,
Published by
Business Wire
03 Apr 12 Docetaxel Dominates First-Line Metastatic Castrate-Resistant Prostate Cancer Treatment, But Total Patient Share of Zytiga and Jevtana Reach Nearly 50 Percent in the Second and Third-Line Settings According to Surveyed Physicians BioTrends Research Group LLC,
Published by
Business Wire
29 Mar 12 Despite Significant Advances in the Treatment of Chronic Myeloid Leukemia (CML) Over the Last Decade, Hematologist-Oncologists Report High Unmet Need for New Therapies in TKI Treatment-Resistant Patients BioTrends Research Group LLC,
Published by
Business Wire
29 Mar 12 U.S. Neurologists Adopt a “Wait and See” Attitude Regarding Recent Gilenya-Treated Patient Deaths, While Embracing the Anti-JC Virus Antibody Assay in Their Practices, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
28 Mar 12 Rheumatologists Continue to Increase Their Use of Biologics for the Treatment of RA Compared to a Year Ago, but Areas of Improvement Exist for This Drug Class BioTrends Research Group LLC,
Published by
Business Wire
22 Mar 12 While Rheumatologists Are Gaining More Familiarity and Experience with KRYSTEXXA, Less Than One-Third of Physicians Stated They Used It One Year Post Launch BioTrends Research Group LLC,
Published by
Business Wire
15 Mar 12 Despite Concerns over the Price of Dificid, 46 Percent of ID Specialists and 32 Percent of Internists Have Already Prescribed It to Their CDAD Patients Six Months Post-Launch, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
15 Mar 12 Orencia SC Seems to be Growing the Orencia Brand, with the Majority of Patients Initiated on Orencia SC Being Switched from the Current Market Leaders for RA Therapy, According to Report by BioTrends Research Group BioTrends Research Group LLC,
Published by
Business Wire
15 Mar 12 Nephrologists Agree That There is a High Unmet Need for an Effective Treatment to Slow Renal Disease Progression in Polycystic Kidney Disease, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
21 Feb 12 Eylea Has Already Begun to Be Used by U.S. Retinal Specialists One Month Post-Launch, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
23 Jan 12 Newly Released BioTrends Chart Audit Report Identifies Variations in Treatment Patterns between DMA Brands and EU5 Countries through Analysis of “Real World” DMA-Treated MS Patients BioTrends Research Group LLC,
Published by
Business Wire
16 Jan 12 Despite No Current Approval of Janssen’s Zytiga in Asymptomatic/Minimally Symptomatic MCRPC, 31% of Surveyed Physicians Report Decreased Use of Dendreon’s Provenge Because Zytiga is Available for Later Lines of Treatment BioTrends Research Group LLC,
Published by
Business Wire
12 Jan 12 Despite Rapidly Adopting Molecular Screening for Xalkori, Medical Oncologists are Having Difficulty Finding Patients BioTrends Research Group LLC,
Published by
Business Wire
21 Dec 11 Newly Released Study by BioTrends Highlights “Real World” Use of Benlysta in Patients with Systemic Lupus Erythematosus (SLE) BioTrends Research Group LLC,
Published by
Business Wire
13 Dec 11 Even with Limited European Access, Gilenya Trial and Uptake Is Having a Significant Impact on the EU5 DMA Market Landscape, According to a Recent BioTrends Report BioTrends Research Group LLC,
Published by
Business Wire
30 Nov 11 The Majority of Gout Patients on Uric Acid Lowering Therapy Fail to Achieve Control of Serum Urate Levels Despite the Availability of Newer Treatment Options Such as Takeda’s Uloric, Menarini/Ipsen’s Adenuric and Savient Pharmaceuticals’ Krystexxa BioTrends Research Group LLC,
Published by
Business Wire
29 Nov 11 Gastroenterologists Already Very Comfortable with the Use of Abbott/Eisai’s Humira in Ulcerative Colitis and Anticipate Significant Growth Following FDA Approval for this Indication BioTrends Research Group LLC,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.